日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin

在成人糖尿病患者中,胰岛素门冬生物类似药SAR341402与原研胰岛素门冬的疗效、安全性和免疫原性比较(GEMELLI 1):按既往餐时胰岛素类型进行的亚组分析

Shah, Viral N; Franek, Edward; Wernicke-Panten, Karin; Pierre, Suzanne; Mukherjee, Bhaswati; Sadeharju, Karita

Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1)

胰岛素门冬生物类似药 SAR341402 与原研胰岛素门冬在接受每日多次注射联合胰岛素甘精治疗 26 周的糖尿病患者中的疗效和安全性:一项随机开放标签试验 (GEMELLI 1)

Garg, Satish K; Wernicke-Panten, Karin; Wardecki, Marek; Kramer, Daniel; Delalande, Francois; Franek, Edward; Sadeharju, Karita; Monchamp, Travis; Mukherjee, Bhaswati; Shah, Viral N

Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial

在同时使用甘精胰岛素的糖尿病患者中,胰岛素门冬生物类似药SAR341402与原研胰岛素门冬相比的安全性、免疫原性和血糖控制:GEMELLI 1试验的12个月结果

Garg, Satish K; Wernicke-Panten, Karin; Wardecki, Marek; Kramer, Daniel; Delalande, Francois; Franek, Edward; Sadeharju, Karita; Monchamp, Travis; Miossec, Patrick; Mukherjee, Bhaswati; Shah, Viral N

Enterovirus infections as a risk factor for type I diabetes: virus analyses in a dietary intervention trial

肠道病毒感染是 1 型糖尿病的危险因素:一项饮食干预试验中的病毒分析

Sadeharju, K; Hämäläinen, A-M; Knip, M; Lönnrot, M; Koskela, P; Virtanen, S M; Ilonen, J; Akerblom, H K; Hyöty, H